60
Participants
Start Date
July 6, 2020
Primary Completion Date
July 31, 2028
Study Completion Date
July 31, 2028
Bosutinib
"Patients with R/I disease are enrolled at a dose of 400 mg/m2 (DL2B) based on tolerability and PK analysis. Once the RP2D for R/I patients (RP2DR/I) is determined in the Phase 1, subsequent patients with R/I disease will be enrolled at the RP2DR/I for this subpopulation for the Phase 2 component of the study (see section 1.6.3 and section 3 for details).~\- Patients with newly diagnosed disease are being enrolled on Phase 2 component only, at RP2DND dose of 300 mg/m2. (see section 1.6.3 and section 3 for details)"
The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
Roswell Park Cancer Institute, Buffalo
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Lehigh Valley Hospital-Cedar Crest, Bethlehem
Children's Hospital of Philadelphia, Philadelphia
Alfred I duPont Hospital for Children, Wilmington
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Inova Fairfax Hospital, Falls Church
Children's Hospital of The King's Daughters, Norfolk
Carolinas Medical Center/Levine Cancer Institute, Charlotte
University of Florida Health Science Center - Gainesville, Gainesville
Nemours Children's Hospital, Orlando
Golisano Children's Hospital of Southwest Florida, Fort Myers
Children's Hospital of Alabama, Birmingham
Vanderbilt University/Ingram Cancer Center, Nashville
East Tennessee Childrens Hospital, Knoxville
Saint Jude Children's Research Hospital, Memphis
Norton Children's Hospital, Louisville
Nationwide Children's Hospital, Columbus
Rainbow Babies and Childrens Hospital, Cleveland
Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Riley Hospital for Children, Indianapolis
Blank Children's Hospital, Des Moines
Children's Hospital of Wisconsin, Milwaukee
Children's Mercy Hospitals and Clinics, Kansas City
UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
M D Anderson Cancer Center, Houston
Dell Children's Medical Center of Central Texas, Austin
Phoenix Childrens Hospital, Phoenix
Children's Specialty Center of Nevada II, Las Vegas
Kaiser Permanente Downey Medical Center, Downey
Loma Linda University Medical Center, Loma Linda
Children's Hospital of Orange County, Orange
Lucile Packard Children's Hospital Stanford University, Palo Alto
Kaiser Permanene-Oakland, Oakland
Kapiolani Medical Center for Women and Children, Honolulu
Seattle Children's Hospital, Seattle
Arkansas Children's Hospital, Little Rock
Dana-Farber/Harvard Cancer Center, Boston
Hackensack University Medical Center, Hackensack
Morristown Medical Center, Morristown
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick
Rhode Island Hospital, Providence
CHU Lyon/Hospices Civils de Lyon, Lyon
Hopital Armand Trousseau, Paris
Hopital Robert Debré, Paris
Universitätsklinikum Erlangen, Erlangen
San Gerardo Hospital, Monza
Ospedale Pediatrico Bambino Gesu, Rome
Ospedale Regina Margerita, Torino
Erasmus Medical Center - Sophia Children's Hospital, Rotterdam
Prinses Maxima centrum voor kinderoncologie, Utrecht
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Niño Jesús, Madrid
University Children's Hospital, Zurich
Birmingham Children's Hospital, Birmingham
The Royal Marsden NHS Foundation Trust, London
Collaborators (2)
Erasmus Medical Center
OTHER
Dutch Childhood Oncology Group
OTHER
Innovative Therapies for Children with Cancer
UNKNOWN
Pfizer
INDUSTRY
Children's Oncology Group
NETWORK